The major goal of our type III transitional COBRE is to provide state of the art genomic and transgenic core services to the Brown University community and affiliated centers in the Northeast while preparing to transition to independent suport in the next five years. The scientific theme of the Center developed with type II COBRE support was cancer signaling networks. This general scientific theme will be continued but we as a center are poised to provide the research infrastructure for a wider range of scientific projects than were supported initially in the type II COBRE. The pilot project mechanism associated with the type III COBRE will be used to nucleate collaborative efforts by groups of faculty focusing on significant scientific problems that can immediately translate into multi-PI and/or program project applications. The research cores originally proposed were Mouse Transgenics, Imaging, Genomics and Bioinformatics. The first three carried over from the type I COBRE while the latter was established as a new core facility. The Bioinformatics core was only briefly supported by the type II COBRE as it evolved into an independent center (Center for Computational Molecular Biology). The Imaging core was also graduated from COBRE support and now functions as an independent facility. The imaging core has grown exponentially and is a major resource for investigators at Brown and in the state. We have a track record of using COBRE resources to develop solid research cores whose scientific focus allows them to achieve independence from this mechanism. Our remaining two cores for which we are requesting support are quickly becoming more heavily relied on by the scientific community here in Rhode Island. We will continue to improve these cores to the point where they can be independently supported by a combination of user fees, individual and program-type grant support, and University cost-sharing when needed.
The research resources that are proposed in this application will foster a broad range of cancer related research programs at Brown and its affiliates in the State of Rhode Island. The state of the art core facilities in genomics and transgenics are critical to maintaining our position of excellence in the scientific community.
|Kao, Hung-Teh; Ryoo, Kanghyun; Lin, Albert et al. (2017) Synapsins regulate brain-derived neurotrophic factor-mediated synaptic potentiation and axon elongation by acting on membrane rafts. Eur J Neurosci 45:1085-1101|
|Scarborough, Nicole M; Godaliyadda, G M Dilshan P; Ye, Dong Hye et al. (2017) Dynamic X-ray diffraction sampling for protein crystal positioning. J Synchrotron Radiat 24:188-195|
|Taggart, Allison J; Lin, Chien-Ling; Shrestha, Barsha et al. (2017) Large-scale analysis of branchpoint usage across species and cell lines. Genome Res 27:639-649|
|Monahan, Zachary; Ryan, Veronica H; Janke, Abigail M et al. (2017) Phosphorylation of the FUS low-complexity domain disrupts phase separation, aggregation, and toxicity. EMBO J 36:2951-2967|
|Conicella, Alexander E; Zerze, Gül H; Mittal, Jeetain et al. (2016) ALS Mutations Disrupt Phase Separation Mediated by ?-Helical Structure in the TDP-43 Low-Complexity C-Terminal Domain. Structure 24:1537-49|
|Yilmaz, Atilgan; Kattamuri, Chandramohan; Ozdeslik, Rana N et al. (2016) MuSK is a BMP co-receptor that shapes BMP responses and calcium signaling in muscle cells. Sci Signal 9:ra87|
|Uzun, Alper; Schuster, Jessica; McGonnigal, Bethany et al. (2016) Targeted Sequencing and Meta-Analysis of Preterm Birth. PLoS One 11:e0155021|
|Dimitriadi, Maria; Derdowski, Aaron; Kalloo, Geetika et al. (2016) Decreased function of survival motor neuron protein impairs endocytic pathways. Proc Natl Acad Sci U S A 113:E4377-86|
|Francois-Vaughan, Heather; Adebayo, Adeola O; Brilliant, Kate E et al. (2016) Persistent effect of mTOR inhibition on preneoplastic foci progression and gene expression in a rat model of hepatocellular carcinoma. Carcinogenesis 37:408-419|
|Brodsky, Alexander S; Xiong, Jinjun; Yang, Dongfang et al. (2016) Identification of stromal ColX?1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer. BMC Cancer 16:274|
Showing the most recent 10 out of 54 publications